EQS-News: MEDIQON Group AG: Executive Board contract of Jan-Hendrik Mohr extended
|
EQS-News: MEDIQON Group AG
/ Key word(s): Personnel
MEDIQON Group AG: Executive Board contract of Jan-Hendrik Mohr extended
16.02.2023 / 09:58 CET/CEST
The issuer is solely responsible for the content of this announcement.
MEDIQON Group AG: Executive Board contract of Jan-Hendrik Mohr extended
Yesterday, the company's Supervisory Board unanimously extended the contract of CEO Jan-Hendrik Mohr until December 31, 2027.
Supervisory Board Chairman Dr. Mathias Saggau commented:
"We are happy that Jan wants to continue to drive the growth of MEDIQON Group AG and committed to lead the next chapter of our development. This ensures continuity in the management of the Group for a long time to come."
Jan-Hendrik Mohr:
"I’m grateful for the great trust placed in me and I look forward to shape the future of MEDIQON Group AG in the next years as part of a great team!"
16.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
MEDIQON Group AG |
|
Herzog-Adolph-Strasse 2 |
|
61462 Königstein im Taunus |
|
Germany |
| Phone: |
+49 (0) 6174-9687040 |
| Fax: |
+49 (0) 6174-9687043 |
| E-mail: |
[email protected] |
| Internet: |
www.mediqon-group.de |
| ISIN: |
DE0006618309, DE000A254TL0 |
| WKN: |
661830, A254TL |
| Listed: |
Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart |
| EQS News ID: |
1561633 |
| |
| End of News |
EQS News Service |
1561633 16.02.2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
3,21 |
2,64 |
0,10 |
1,08 |
28,66 |
42,07 |
0,00 |
| EBITDA1,2 |
0,72 |
8,99 |
-0,44 |
-0,61 |
6,21 |
10,50 |
0,00 |
| EBITDA-Marge3 |
22,43 |
340,53 |
-440,00 |
-56,48 |
21,67 |
24,96 |
|
| EBIT1,4 |
0,51 |
8,65 |
-5,51 |
-2,56 |
0,94 |
2,51 |
0,00 |
| EBIT-Marge5 |
15,89 |
327,65 |
-5.510,00 |
-237,04 |
3,28 |
5,97 |
0,00 |
| Jahresüberschuss1 |
0,54 |
7,51 |
-5,01 |
-2,27 |
-2,27 |
-6,60 |
0,00 |
| Netto-Marge6 |
16,82 |
284,47 |
-5.010,00 |
-210,19 |
-7,92 |
-15,69 |
0,00 |
| Cashflow1,7 |
0,75 |
7,85 |
-5,00 |
-1,13 |
2,87 |
5,69 |
0,00 |
| Ergebnis je Aktie8 |
0,24 |
3,04 |
-1,50 |
-0,18 |
0,38 |
0,05 |
0,23 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Chapters Group |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 661830 |
21,000 |
Kaufen |
346,48 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 42,00 |
17,40 |
2,41 |
66,67 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 3,55 |
60,86 |
8,24 |
36,41 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
09.07.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
29.09.2023 |
|
24.05.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| 3,95% |
26,63% |
14,75% |
46,85% |
|
|
MEDIQON Group AG DE0006618309